Definitive Contract 75N93022C00032
Award Date
6/30/22
Potential Completion Date
6/29/24
Potential Value
$600K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Integral Molecular Inc.
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Philadelphia, PA 19104, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
9
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,500,000.00 Firm Fixed Price Definitive Contract to Integral Molecular Inc., a small business biotechnology company, for the development of antibody reagents to support immunologic analysis of underrepresented mammalian models. This contract is part of the Small Business Innovation Research (SBIR) Program Phase II. Integral Molecular specializes in membrane protein research and has received prior contracts and grants...
This is a $600,000 Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Integral Molecular Inc., a biotechnology company specializing in membrane protein research and therapeutic antibody development. The contract is for the development of "Reagents for Immunologic Analysis of Non-mammalian and Underrepresented Mammalian Models", supporting...
The Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $16,200 purchase order to Integral Molecular Inc. for membrane proteome array services (AMBIS #2194825). The firm fixed price contract will be performed in Philadelphia, Pennsylvania from November 21, 2023 through January 31, 2024. As part of NIH's efforts to advance biomedical research, this award will provide Integral Molecular services to analyze protein...
This contract award is to Integral Molecular Inc., a biotechnology company specializing in membrane protein research and antibody development. The contract, valued at $150,000.00, was awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), under the Small Business Innovation Research (SBIR) program. The contract is for a Phase I research project focused on biomedical research. It is designated as a total small business set-aside. Integral Molecular...
This is a $7,910,444.00 definitive cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to Integral Molecular Inc. The contract is for discovering and characterizing B cell epitopes against the viral pathogens Rift Valley Fever Virus, Crimean-Congo Hemorrhagic Fever Virus, and Enterovirus D68. The contract has a period of performance from September 16, 2024 to September 15, 2029 and was not set...
Integral Molecular Inc. has been awarded a $20,000 firm fixed price purchase order by the Department of Health and Human Services' National Institutes of Health National Cancer Institute. This contract has no set-aside designation. The contract is for MPA+IND SCREEN services to support the National Cancer Institute's screening and research programs. As a biotechnology company focused on membrane proteins and disease targets, Integral Molecular will likely provide biological materials, testing,...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), awarded a $33,273,522 cost-plus-fixed-fee definitive contract to Anivive Lifesciences Inc., a self-certified small disadvantaged business, to develop vaccine candidates for biodefense and emerging infectious diseases. This contract, awarded on June 7, 2024, is part of NIAID's Broad Agency Announcement (BAA) research program and has a completion date of June 1, 2026. The contract...
This $599,526 Firm Fixed Price contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Enepret Incorporated, a for-profit manufacturer located in Lexington, Kentucky. The contract is for "Adjuvant Discovery and Down-Selection for Vaccines against Infectious and Immune-Mediated Diseases" and supports NIAID's broader program goals related to "A More Durable and Universal Adjuvanted...
This is a $4,259,653.00 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS), to Inimmune Corp, a biotechnology company, for the development of a synthetic AS01-like adjuvant system for influenza vaccines. The contract has an ultimate completion date of September 29, 2028 and is a cost-type contract without a fee. This contract is not set aside for...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $449,984 firm fixed-price contract to Applied Biotechnology Institute Inc., a veteran-owned small business, to develop a mucosal prophylactic vaccine against coccidioidomycosis. The contract, with a completion date of August 30, 2018, is a direct result of NIAID's research efforts in the area of allergy and infectious diseases. Applied Biotechnology Institute Inc. has previously received federal grants from NIAID and the...